

SPH.L

Decapinol® Agreement

Sinclair Pharma plc ("Sinclair" or "the Company": SPH:L), the international specialty pharma company, today announces a new agreement with Laboratoires Expanscience SA ("Expanscience") for the distribution of its proprietary dental hygiene product for gingivitis, based on delmopinol, in France and the French overseas 'DOM-TOM' territories.

Set up in 1950, Expanscience is a leading French company in the areas of dermo-cosmetics, rheumatology, oral care, dermatology and cosmetic active ingredients. The company has subsidiaries in eight countries, as well as a global partnering network spanning 59 markets. In 2009 Expanscience sales totalled €233 million with 964 employees (www.expanscience.com).

The distribution agreement covers all four products in the Delmopinol range (mouthwash, toothpaste, gel and spray), which will be promoted by the Expanscience dental representatives to dentists and pharmacists under Expanscience's proprietary brand name. It is anticipated that the first products will be launched on the French market during 2011.

Chris Spooner, CEO of Sinclair Pharma plc, commented, "We are delighted to be introducing Delmopinol to the French market through this new agreement with Expanscience. This deal is in line with our strategy for Decapinol and we expect this to be the first of several deals covering Decapinol in Europe and the United States to be announced over the next 12 months."

Ends

For further information please contact:

Sinclair Pharma plc

Tel: +44 (0) 1483 410 600

Chris Spooner, CEO
Alan Olby, CFO

Singer Capital Markets Ltd

Tel: +44 (0)20 3205 7500

Shaun Dobson
Claes Spång

Biddicks, Financial Public Relations

Tel: +44 (0)20 7448 1000

Shane Dolan

Notes to Editors:

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy,

Germany and Spain, and an extensive marketing partner network across selected developed & emerging markets.

About Decapinol

Decapinol is Sinclair Pharma plc's proprietary dental hygiene product for gingivitis, based on the first in class anti-biofilm medical active, delmopinol. Decapinol is available as a mouthwash, toothpaste, gel and spray. Decapinol is currently sold in various European and Asian countries.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.